VRNA News and Press, Verona Pharma plc From 08/08/23

2023-08-08 16:44:55 ET Summary Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for its primary drug candidate that is targeting the large and growing COPD market. The stock has ris...

2023-08-05 08:21:09 ET Verona Pharma plc. (VRNA) Q2 2023 Earnings Conference Call August 03, 2023, 09:00 AM ET Company Participants David Zaccardelli - Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Christoph...

2023-08-03 02:02:02 ET Verona Pharma press release ( NASDAQ: VRNA ): Q2 GAAP EPS of -$0.01 beats by $0.20 . Cash and cash equivalents at June 30, 2023, were $270.7 million (December 31, 2022: $227.8 million). The Company believes cash and cash equivalents at June 3...

NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. E...

LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that senior management will present a company ove...

LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the seco...

LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care Medicine (“AJRCCM”) has published results from its Phase 3...

LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for app...

2023-05-28 09:08:14 ET Summary Verona Pharma, a clinical-stage biopharmaceutical company, is making strides with its novel COPD treatment, ensifentrine, exhibiting promise in addressing significant unmet needs in the COPD market. The company's Q1 2023 financial report showcases a ...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...